SR One Capital Management LP Makes New Investment in enGene Holdings Inc. (NASDAQ:ENGN)

SR One Capital Management LP acquired a new stake in enGene Holdings Inc. (NASDAQ:ENGN) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 500,000 shares of the company’s stock, valued at approximately $4,715,000. enGene accounts for 1.5% of SR One Capital Management LP’s holdings, making the stock its 8th biggest holding. SR One Capital Management LP owned 1.13% of enGene as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Altitude Crest Partners Inc. purchased a new position in enGene in the first quarter worth approximately $2,039,000. Omega Fund Management LLC acquired a new position in shares of enGene during the fourth quarter worth $10,441,000. Janus Henderson Group PLC purchased a new position in enGene in the first quarter valued at $17,095,000. Finally, BVF Inc. IL acquired a new stake in enGene in the fourth quarter valued at $20,777,000. 64.16% of the stock is owned by institutional investors and hedge funds.

enGene Stock Up 0.7 %

enGene stock opened at $7.21 on Friday. The stock has a 50-day simple moving average of $7.30 and a 200-day simple moving average of $11.17. The company has a market capitalization of $318.44 million, a P/E ratio of -4.34 and a beta of -0.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 42.80 and a current ratio of 19.52. enGene Holdings Inc. has a fifty-two week low of $4.94 and a fifty-two week high of $43.00.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.05. Equities research analysts expect that enGene Holdings Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ENGN has been the topic of a number of recent analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a report on Wednesday, September 11th. Oppenheimer initiated coverage on shares of enGene in a report on Wednesday, August 28th. They set an “outperform” rating and a $30.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, enGene presently has a consensus rating of “Buy” and a consensus price target of $33.67.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.